Get the Stockscreener App
1.34
2.90%
-0.04
Zentalis Pharmaceuticals Inc stock is traded at $1.34, with a volume of 416.41K.
It is down -2.90% in the last 24 hours and up +12.61% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.38
Open:
$1.34
24h Volume:
416.41K
Relative Volume:
0.45
Market Cap:
$96.42M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.2952
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-8.84%
1M Performance:
+12.61%
6M Performance:
-22.99%
1Y Performance:
-64.74%
1-Day Range:
$1.31
$1.385
1-Week Range:
$1.31
$1.485
52-Week Range:
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.34 | 99.29M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
How does Zentalis Pharmaceuticals Inc. generate profit in a changing economyChart Pattern Growth Plan For Every Investor - jammulinksnews.com
When is the best time to exit Zentalis Pharmaceuticals Inc.Free Market Entry and Exit Point Tips - Newser
What institutional investors are buying Zentalis Pharmaceuticals Inc. stockBest Dividend Ideas For Beginners - jammulinksnews.com
Real time social sentiment graph for Zentalis Pharmaceuticals Inc.Free Technical Entry Strategy for Beginners - Newser
Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Friday - Defense World
Sentiment analysis tools applied to Zentalis Pharmaceuticals Inc.Free Technical Stock Breakout Predictions - Newser
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionFree Market Entry and Exit Point Tips - Newser
Visualizing Zentalis Pharmaceuticals Inc. stock with heatmapsTechnical Long-Term Outlook and Recap Guide - Newser
Will Zentalis Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsTen-Year Sector Performance and Summary Analysis - Newser
Published on: 2025-07-29 18:20:19 - metal.it
Published on: 2025-07-29 13:48:57 - metal.it
How Efficient Is Zentalis Pharmaceuticals Inc. at Controlling Operating CostsBollinger Band Squeeze and Expansion Analysis - Newser
Can Zentalis Pharmaceuticals Inc. Escape Recent Bear ChannelAI Screening for Swing Trade Picks Finds Momentum - metal.it
Does Zentalis Pharmaceuticals Inc. stock perform well during market downturnsUnlock your portfolio’s full growth potential - jammulinksnews.com
Is Zentalis Pharmaceuticals Inc. a growth stock or a value stockFree Trend-Following Techniques - jammulinksnews.com
How does Zentalis Pharmaceuticals Inc. compare to its industry peersGet expert analysis on top stock picks - jammulinksnews.com
What are Zentalis Pharmaceuticals Inc. company’s key revenue driversUnlock exclusive stock market forecasts - jammulinksnews.com
What catalysts could drive Zentalis Pharmaceuticals Inc. stock higher in 2025Unlock real-time stock alerts for quick profits - jammulinksnews.com
What is the dividend policy of Zentalis Pharmaceuticals Inc. stockSuperior returns - jammulinksnews.com
When is Zentalis Pharmaceuticals Inc. stock expected to show significant growthMaximize your returns with smart trade entries - jammulinksnews.com
What are analysts’ price targets for Zentalis Pharmaceuticals Inc. in the next 12 monthsMaster the art of timing market moves - jammulinksnews.com
Is Zentalis Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis InsideRisk Aware High Growth Picks - metal.it
How volatile is Zentalis Pharmaceuticals Inc. stock compared to the marketMassive profits - jammulinksnews.com
What is the risk reward ratio of investing in Zentalis Pharmaceuticals Inc. stockInvest smarter with real-time trading signals - jammulinksnews.com
Sectors Driving Future Growth for Zentalis Pharmaceuticals Inc. StockFree Access to Community - Newser
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyConsistent High Return Strategy - Newser
What drives Zentalis Pharmaceuticals Inc. stock priceFree Technical Analysis Support - PrintWeekIndia
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company - Yahoo Finance
Is Zentalis Pharmaceuticals Inc. a good long term investmentFree Technical Analysis Support - Autocar Professional
What analysts say about Zentalis Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional
Zentalis Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated capital growth - Autocar Professional
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):